On May 28, Agilent Technologies rose 6.77% in pre-market trading, trading at $122.73/share, with trading volume of $16,500.

The rally was driven by strong fiscal Q2 results and an upward revision to full-year guidance. Agilent reported adjusted EPS of $1.49, beating the consensus estimate of $1.41 by 5.67% and representing a 13.74% year-over-year increase. Revenue came in at $1.835 billion, surpassing the expected $1.799 billion and growing approximately 10.2% year-over-year. The company raised its full-year adjusted EPS outlook to $6.00–$6.10, up from the prior range of $5.90–$6.04, citing strong demand for laboratory research and diagnostic tools. Management highlighted GLP-1 drug momentum as a key growth driver, contributing roughly 20% growth year-to-date. Additionally, RBC Capital Markets initiated coverage with an Outperform rating and a $153 price target, citing product cycle momentum across key instrument platforms and tailwinds from US pharmaceutical reshoring.

Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and consumables for laboratory workflows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)